ABBVIE INC. vs. Xeris Biopharma Holdings, Inc. Common Stock
ABBVIE INC. (ABBV) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| ABBV | XERS | |
|---|---|---|
| Market Cap | $466.45 billion | $1.50 billion |
| Revenue (TTM) | $64.39 billion | $33.38 million |
| Net Income (TTM) | $6.32 billion | $-83,783,000 |
ABBV leads on 3 of 3 size & scale factors.
Valuation
| ABBV | XERS | |
|---|---|---|
| P/E Ratio | 74.56 | — |
| Price / Book | -79.22 | 75.17 |
| Price / Sales | 7.24 | 44.79 |
ABBV leads on 2 of 2 valuation factors.
Profitability
| ABBV | XERS | |
|---|---|---|
| Net Margin | 9.81% | -251.01% |
| Return on Equity | -107.29% | -421.27% |
ABBV leads on 2 of 2 profitability factors.
Dividend
| ABBV | XERS | |
|---|---|---|
| Dividend Yield | 2.62% | — |
| Payout Ratio | 195.48 | — |
ABBV and XERS split the dividend factors evenly.
Risk & Sentiment
| ABBV | XERS | |
|---|---|---|
| Short Interest | 0.85% | 0.10% |
XERS leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, XERS overview, XERS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.